Investors may be wondering whether Lakefront Biotherapeutics at €24.94 is starting to look like value, or if the risks still outweigh the potential upside. The stock has risen 2.2% over the past week and 6.6% over the last month, although it remains down 11.4% year to date and has fallen 1.7% over the past year. Recent coverage has focused on Lakefront Biotherapeutics as a smaller biotech stock that has seen substantial 3 year and 5 year share price declines, which can draw interest from...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality growth stocks to buy. On June 4, Gilead Sciences and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines, a strategic move designed to bolster their inflammation and immunology pipelines. The centerpiece of this acquisition is gamgertamig (OM336), a clinical-stage T cell engager being developed as […]

Lakefront Biotherapeutics NV ( AMS:LKFT ) last week reported its latest quarterly results, which makes it a good time...

Galapagos (NASDAQ:GLPG) executives used the company’s first-quarter 2026 earnings call to highlight what Chief Executive Officer Henry Gosebruch described as a “real transformation,” including portfolio changes, management and board updates, and an upcoming corporate rebrand to Lakefront Biotherapeu

We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Galapagos NV is among the most undervalued stocks to invest in. TheFly reported on April 7 that RBC Capital Markets adjusted its outlook on GLPG, reducing its price target from $33 to $28 while maintaining a Sector Perform rating. The […]

Galapagos NV (NASDAQ:GLPG) is one of the 7 Fastest Growing European Stocks to Invest In. On March 31, 2026, Galapagos NV (NASDAQ:GLPG) announced a binding agreement with Gilead Sciences (NASDAQ:GILD) related to Gilead’s planned acquisition of Ouro Medicines, a U.S.-based biotech focused on T cell engager therapies for autoimmune diseases. The deal includes access to […]

Galapagos (NASDAQ:GLPG) said it has entered into a binding collaboration agreement with Gilead focused on Gamgertamig, a BCMA x CD3 T-cell engager being developed for autoimmune diseases. Chief Executive Officer Henry Gosebruch said the deal follows “advanced discussions” disclosed the prior week an

Gilead Sciences (NasdaqGS:GILD) has entered a definitive agreement to acquire Ouro Medicines, expanding into T cell engager therapies for autoimmune diseases. The company has also signed a collaboration agreement with Galapagos NV to advance T cell engager therapies. These moves affect Gilead's research pipeline and potential future treatment offerings. Gilead Sciences, trading at $136.34, has seen a 12.1% return year to date and a 24.9% return over the past year. Over 3 years, the stock...

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. On March 23, The Wall Street Journal reported that Gilead Sciences, Inc. (NASDAQ:GILD) plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion. The company also intends to develop the acquired […]

GILD expands into autoimmune therapies with an acquisition deal with Ouro Medicines, adding OM336 and advancing its push into next-gen immunology platforms.